PolyPid(PYPD) - 2023 Q1 - Earnings Call Presentation

Executive Vice President heading R&D, and Clinical & Regulatory Affairs Balance Sheet • An early stop to the trial can occur if the efficacy of DPLEX100 is better than expected • Opportunity to define the targeted patient enrollment range for the SHIELD I study 5 Total US addressable market (TAM) for D-PLEX100 is over 12.2M procedures Number of surgeries in DPLEX target indications (M) 4.42 12.15 2.44 0.47 4.82 Abdominal Gyn & Uro Sternum Orthopedic Total | --- | --- | |-------|----------------------------- ...